JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M409382200 on September 22, 2004

J. Biol. Chem., Vol. 279, Issue 49, 51331-51337, December 3, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/49/51331    most recent
M409382200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshida, M.
Right arrow Articles by Kawano, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, M.
Right arrow Articles by Kawano, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Gly-Gly Linker Region of the Insect Cytokine Growth-blocking Peptide Is Essential for Activity*

Masanobu Yoshida{ddagger}, Tomoyasu Aizawa§, Takashi Nakamura{ddagger}, Kunio Shitara{ddagger}, Yoichi Hayakawa¶, Kimiaki Matsubara{ddagger}, Kazunori Miura{ddagger}, Takahide Kouno{ddagger}, Kevin D. Clark||, Michael R. Strand||, Mineyuki Mizuguchi{ddagger}, Makoto Demura§, Katsutoshi Nitta§, and Keiichi Kawano{ddagger}§**

From the {ddagger}Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan, the §Division of Biological Sciences, Graduate School of Science, Hokkaido University, Sapporo 060-0810, Japan, the Department of Agriculture, Saga University, Saga 840-8502, Japan, and the ||Department of Entomology, University of Georgia, Athens, Georgia 30602

Received for publication, August 16, 2004 , and in revised form, September 17, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Growth-blocking peptide (GBP) is a 25-amino acid cytokine isolated from the lepidopteran insect Pseudaletia separata. GBP exhibits various biological activities such as regulation of larval growth of insects, proliferation of a few kinds of cultured cells, and stimulation of a class of insect immune cells called plasmatocytes. The tertiary structure of GBP consists of a well structured core domain and disordered N and C termini. Our previous studies revealed that, in addition to the structured core, specific residues in the unstructured N-terminal region (Glu1 and Phe3) are also essential for the plasmatocyte-stimulating activity. In this study, a number of deletion, insertion, and site-directed mutants targeting the unstructured N-terminal residues of GBP were constructed to gain more detailed insight into the mode of interaction between the N-terminal region and GBP receptor. Alteration of the backbone length of the linker region between the core structure and N-terminal domain reduced plasmatocyte-stimulating activity. The substitutions of Gly5 or Gly6 in this linker region with more bulky residues, such as Phe and Pro, also remarkably reduced this activity. We conclude that the interaction of GBP with its receptor depends on the relative position of the N-terminal domain to the core structure, and therefore the backbone flexibility of Gly residues in the linker region is necessary for adoption of a proper conformation suited to receptor binding. Additionally, antagonistic experiments using deletion mutants confirmed that not only the core domain but also the N-terminal region of GBP are required for "receptor-binding," and furthermore Phe3 is a binding determinant of the N-terminal domain.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Growth-blocking peptide (GBP)1 was initially identified as a peptidyl hormone that retards the larval development of the armyworm Pseudaletia separata (1–4). High concentrations of GBP induce significant reductions in larval growth, whereas low concentrations of GBP stimulate larval growth, thus suggesting that GBP acts as a growth factor in insects. Subsequent studies have shown that GBP has multiple functions, including stimulation of specific insect immune cells (plasmatocytes), proliferation of various types of cultured cells, and paralysis of larvae (5–7). Furthermore, our recent study showed that GBP stimulates cell proliferation of human keratinocyte cells through direct binding and activation of epidermal growth factor receptors (8).

GBP is a 25-amino acid peptide containing a disordered N terminus (residues 1–6) and a structured core (residues 7–22) defined by a disulfide bond and a short antiparallel {beta}-sheet (9). Interestingly, both the structured core region of GBP and the disordered N-terminal region are required for biological activity (10). Previous studies demonstrated that the first three residues of the N terminus (Glu-Asn-Phe) of GBP and plasmatocyte spreading peptide (PSP) from Pseudoplusia includens play a critical role in plasmatocyte-stimulating activity (11–13). This Glu-Asn-Phe triad is conserved in the GBP homologues identified from other lepidopteran species. Because of this consensus ENF sequence, these homologues are now referred to as members of the ENF peptide family (Fig. 1) (14). Recent studies using mutants with specific point mutations or alterations to the ENF sequence in GBP as well as PSP showed the possibility that Phe3 interacts with putative receptors in plasmatocytes via its hydrophobic effect (11, 13, 14).



View larger version (63K):
[in this window]
[in a new window]
  		FIG. 1.
Sequence alignment of GBP and other members of the ENF peptide family. GBP from P. separata (P.s. GBP), Mamestra brassicae (M.b. GBP), Spodoptera litura (S.l. GBP) (5), paralitic peptides from Trichoplusia ni (T.n. PP I and II) (27), Heliothis virescens (H.v. PP I and II), Manduca sexta (M.s. PP I and II), Spodoptera exigua (S. e. PP I, II, and III) (7), Antheraea yamamai (A.y. PP) (28), Bombyx mori (B.m. PP) (29), plasmatocyte-spreading peptide from Pseudoplusia includens (P.i. PSP) (6), and cardioactive peptide from Spodoptera eridania (S.e. CAP) (30) were aligned. The residues within the shaded boxes are completely conserved in the family peptides.

 
In the present study we focused on the two glycine residues (Gly5 and Gly6) that are located in the linker region between the well structured core and the N-terminal ENF motif (Fig. 2A). Gly5 and Gly6 are highly conserved within the ENF peptide family. Because it has no side chain, glycine is more flexible than other residues and is often found in areas of the peptide backbone that need to move or hinge (15). We therefore predict that the flexibility of the Gly-Gly sequence in the linker region plays an important role in allowing the N-terminal activation site to interact with receptors. To confirm this idea, we constructed a number of GBP mutants in which various N-terminal residues, mainly Gly5 and Gly6, are specifically altered by substitution or deletion. We then investigated the biological activity of these mutant peptides and their interaction with a putative receptor using bioassays and NMR analysis.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 2.
Solution structure of wild-type GBP and sequences of GBP mutants. A, the ensemble of structures of wild-type GBP determined by Aizawa et al. (9). Backbone atoms are shown as sticks, and 15 NMR structures are superimposed. B, the amino acid sequences of the mutant peptides used in this study.

 

   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Animals—P. separata was reared on an artificial diet at 25 ± 1 °C with a photoperiod of 16 h of light and 8 h of dark (1). Penultimate instar larvae undergoing ecdysis between 2 and 2.5 h after lights on were designated as day 0 last instar larvae (1).

Peptide Preparation—All of the mutants used in this study were prepared by the Escherichia coli expression system. Expression and purification of peptide mutants was performed using our procedure previously established (11). cDNA encoding the entire GBP sequence was used as a template, and polymerase chain reactions were performed with each of the mutated GBP primers. We also used a QuikChange site-directed mutagenesis kit (Stratagene) for construction of recombinant plasmids containing point-mutated GBP sequences. GBP mutants were expressed as thioredoxin fusion proteins and purified with nickel-nitrilotriacetic acid-agarose (Qiagen). The 15N-labeling was achieved by growing the bacteria in minimal medium containing 15NH4Cl as the sole nitrogen source. The purified proteins were cleaved by enterokinase enzyme (Invitrogen) and further purified by reverse phase high performance liquid chromatography (HPLC). The peptides after the HPLC purification were judged to be homogeneous after a second analysis by HPLC. The purity of each mutant was above 95% as estimated from HPLC. We obtained purified GBP mutants at a rate of about 10 mg per liter of LB medium. The purified peptides were further confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (Bruker Daltonics).

Plasmatocyte-stimulating Assay—GBP possesses a hemocyte-stimulating activity that induces a specific class of insect immune cells called plasmatocytes to spread and adhere to foreign surfaces (6, 12). Plasmatocyte-stimulating activities of the prepared GBP mutants were assayed in 96-well culture plates (Nunc) using methods similar to those of Clark et al. (6). Hemocytes were collected from full-grown (Day 5) last instar larvae of the armyworm, and plasmatocytes were isolated from other kinds of hemocytes using Percoll gradients. Plasmatocytes were collected from the 40–60% Percoll interface. The isolated plasmatocytes were washed twice in Excell-400 medium (JRH Scientific) and then resuspended in the same medium (~5.0 x 103 cells/100 µl). Three microliters of various concentrations of each peptide sample was mixed with 57 µl of cell suspension in the wells. The percentage of plasmatocytes spread in an assay was scored 20 min after the mixing by counting about 200 cells from a randomly selected view.

Antagonism Assay—Antagonistic activities were assayed according to the following procedure that was slightly modified from that of the plasmatocyte-stimulating assay mentioned above. The plasmatocyte suspension was prepared using the same procedure as the stimulating assay and was preincubated with the mutant peptides for 10 min at room temperature. Then, the GBP solution was added to the cell mixture (final concentration, 100 nM), and the percentage of spread plasmatocytes was counted after incubation for 20 min by the same procedure as that of the plasmatocyte-stimulating assay.

NMR Spectroscopy—All experiments were carried out on a Bruker DMX-500 spectrometer at 25 °C. The chemical shifts were measured from the internal standard of sodium 2,2-dimethyl-2-silapentane-5-sulfonate. Each mutant of GBP was dissolved at a final concentration of 0.3–0.7 mM in 350–500 µl of buffer containing 90% H2O/10% D2O, with 20 mM sodium phosphate at pH 6.5. All one-dimensional spectra were recorded during suppression of the water signal by WATER-GATE pulse (16). The NMR spectra of 15N-labeled samples were recorded under the same condition with nonlabeled samples except for the peptide concentration range of 1.6–2.7 mM, using {15N-1H} heteronuclear single quantum coherence (HSQC) (17) and 15N-edited NOESY (18). Amido resonance assignments of the G5F and G6F mutants were made on the basis of the previously assigned 1H resonances of wild-type GBP using the measured 15N-edited spectra (9).

15N Relaxation Measurement—Measurements of the longitudinal (T1) and transverse (T2) relaxation times and the heteronuclear nuclear Overhauser effects (NOEs) of 15N nuclei were carried out as described previously (19). All spectra were processed and analyzed using NMR Pipe (20) and PIPP (21). The peak intensities of each cross-peak in a series of two-dimensional NMR data were extracted using NMR Pipe based on the peak position defined by the contour averaging algorithm with the program PIPP. A series of extracted intensity profiles of each cross-peak was used for the calculation of the T1 and T2 relaxation times, using a single-exponential model function. The steady-state 1H-15N NOE values were determined from the ratios of the intensities of the peaks with and without proton saturation.


   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
Mutations in the Unstructured N-terminal Region of GBP Do Not Alter the Structured Core of the Peptide—Prior studies have examined the relationship between GBP structure and function using a variety of mutants (10, 11). These experiments showed that GBP mutants whose secondary structures were disrupted relative to wild type GBP had no activity, implying that the core structure was indispensable for the biological activity (10, 22). However, mutants in the unstructured N-terminal domain, such as a deletion of Glu1, also result in a complete loss of activity despite retaining the native core structure of GBP (10, 13). Experiments with mutants of GBP and PSP clearly showed that both the structure and hydrophobicity of the side chain of Phe3 are important for activity (11, 12). Extensive analyses of PSP mutants at Phe3 indicated that a branched carbon chain with a methylene spacer at the third residue is the minimal structural motif that is required for an active peptide (13). The fact that the three N-terminal residues (an ENF motif) of GBP and PSP are also completely conserved in all ENF family peptides suggests that these three residues may play a critical role in receptor activation. Thus, there has been great interest in the structural and functional relationship between the core domain and the N-terminal disordered region of these peptides. Based on these previous findings, we presumed that the highly conserved Gly residues (Gly-Gly sequence, fifth and sixth residues in GBP) in the "linker" region connecting the structured core and the ENF motif could perform a key role in this peptide as a flexible hinge-like element. To clarify this role, we produced a series of mutants modified in this linker region (Fig. 2B). Before assaying for activity, we first determined using 1H NMR spectroscopy whether these mutations had any effects on the conformation of the core domain. One-dimensional NMR spectra of the amide proton region of GBP and all the mutants constructed in this study, except for (3–25)-GBP and (4–25)-GBP, are shown in Fig. 3. If specific mutations in the N-terminal region of GBP were to perturb the tertiary structure of the GBP core domain, some changes or loss of the chemical shift dispersion would be observed in the 1H NMR spectra due to their sensitivity to alterations of the secondary and tertiary structure of the peptide (10, 14). Our experiments showed no significant difference in chemical shift dispersion between wild-type GBP and all the mutants tested. In particular, signals for the amide resonances of Met12, Thr14, and Lys20, all components of the rigid core structure of native GBP, remain unaffected, suggesting that the native core structure of wild-type GBP is conserved. These results confirmed that any effects these mutants may have on activity would be due to local effects in the N-terminal domain rather than conformational changes of the core. These results also suggested that the N-terminal domain of GBP does not contribute to maintaining the tertiary structure of the core domain. Although the 1H NMR spectra of (3–25)-GBP and (4–25)-GBP was not measured, it is reasonable to assume that (3–25)-GBP and (4–25)-GBP also retained the native core structure, because even the (7–25)-GBP mutant without the entire N-terminal region retained the native structure of wild-type GBP.



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 3.
Comparison of the 1H NMR spectra of mutant peptides and wild-type GBP. Each peptide was prepared in 20 mM sodium phosphate buffer at pH 6.5 with 5% D2O, bringing the final concentration to 0.3 mM (wild type, -1G; +1G, G5F, G6F, and G6P), 0.4 mM (G5P), 0.6 mM (G5A and (7–25)) and 0.7 mM (G6A). A, backbone amide resonances are shown, and the three residues that are components of the core structure and that give the most well dispersed signals are labeled for wild-type GBP. B–J, backbone amide resonances of all the mutants except for (3–25)-GBP and (4–25)-GBP.

 
The Length of the Linker Region between the Core Domain and the ENF Motif Is Critical for Activity—As a first step toward examining the role of the distinctive Gly5-Gly6 sequence, we constructed a set of GBP mutants that altered the length of the peptide backbone between the ENF motif and the core domain. These included the deletion mutant ((-1G)-GBP) and the insertion mutant ((+1G)-GBP), in which the ENF motif was positioned, respectively, either closer to or farther from the core domain by addition or subtraction of a Gly residue (Fig. 4A). The (-1G)-GBP lost almost all activity, revealing that a certain minimum length of the backbone "linker" region is required for activity. The (+1G)-GBP also had no activity up to 10 nM and only about one-half of wild-type GBP even at a concentration of 100 nM. These results show that the activity of GBP is affected by the distance of the ENF motif from the core domain. We also prepared a hexapeptide (ENFSGG) that consisted of the first six residues of GBP and a deletion mutant ((7–25)-GBP) lacking the segment corresponding to the hexapeptide. These mutants mimicked a normal GBP molecule in sequence, yet lacked any covalent attachment between the core domain and the N-terminal region (Fig. 4B). As expected, (7–25)-GBP alone did not possess any activity without the critical ENF motif. Moreover, (7–25)-GBP exhibited no activity even when mixed with the N-terminal hexapeptide, indicating that the peptide bond between the N-terminal and core region of GBP is indispensable for activity. Based on these data, we concluded that the proper length of the backbone linker that connects the ENF motif to the core domain is essential in activating GBP receptors.



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 4.
In vitro spreading response of plasmatocytes to mutations in the linker region of GBP. A, two peptides that altered the length of GBP, the glycine deletion mutant (-1G) and the glycine insertion mutant (+1G), were compared with wild-type GBP. B, the N-terminal deletion mutant ((7–25)-GBP) alone and in combination with N-terminal hexapeptide (N6) was compared with wild-type GBP. Activity was assayed by scoring about 200 randomly selected cells after 20 min in culture with 1 nM to 1 µM wild-type or mutant GBPs. Plasmatocytes were scored as spread if they assumed flattened morphologies and were 35 µm along their longest axis. Each bar represents the mean ± S.D. of plasmatocytes spread from four separate measurements.

 
Gly-Gly Linker Substitutions That Restrict the Conformation of the N Terminus Greatly Decrease Activity—To characterize the functional significance of Gly5 and Gly6 in more detail, additional mutants were constructed at these positions using site-directed mutagenesis. If the Gly side chains (hydrogens) are directly involved in receptor activation, then the addition of methyl groups to these Gly residues may have some effect on activity. However, Ala substitutions at either Gly5 or Gly6 (G5A, G6A) had no effect on the activity (Fig. 5), suggesting that the side chains (hydrogens) of these Gly residues are not essential for receptor binding and that the relatively small volume of the linker region and its flexibility may be more important. This prediction was confirmed by using substitution mutants in which Gly5 and Gly6 were substituted with Phe or Pro (G5F, G5P, G6F, and G6P), producing peptides that were much more restricted in their N-terminal polypeptide backbone conformation (Fig. 5). Interestingly, substitutions at these two positions showed strikingly different results. A Phe substitution at Gly6 (G6F) slightly reduced activity: its activity was less at 10 nM than that of the wild-type GBP but was almost same at 100 nM. In contrast, G5F had almost no activity and only exhibited a low level of response at 1 µM, the highest concentration tested. In the case of Pro substitutions, although G5P had no activity even at a concentration of 1 µM (Fig. 5A), the activity of G6P was only reduced about one order of magnitude relative to that of wild-type GBP (Fig. 5B). Thus, the presence of a Gly residue at position 6 in GBP seems to be less important for activity than that at position 5. In addition, the effect of Pro substitutions was more significant than that of Phe substitution in both cases at Gly5 and Gly6 in terms of interfering with the activation of plasmatocytes. This difference is thought to be due to the fact that Pro possesses the strongest stereochemical constraints of any amino acid residue by potentially restricting the degree of freedom of the backbone dihedral angles (15). These results suggest that the high flexibility of the linker residues, especially Gly5, is crucial for interaction with the putative GBP receptor.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 5.
In vitro spreading response of plasmatocytes to substitution mutants in the linker region of GBP. A, plasmatocyte spreading response to the mutants G5A, G5F, and G5P, and B, the mutants G6A, G6F, and G6P. The activities of the mutants were assayed as described in Fig. 4.

 
Phe3 Is Required for Efficient Binding of GBP to Plasmatocytes—Our previous studies identified several residues crucial for the plasmatocyte-stimulating activity of GBP (10, 11), but it has been impossible to distinguish between residues necessary for receptor binding and those involved in receptor activation. To distinguish between binding and activation, we measured the ability of the inactive N-terminal GBP mutants to antagonize the plasmatocyte-stimulating activity of intact GBP. The N-terminal deletion mutants, all of which are inactive analogues of GBP, should be capable of antagonizing GBP if they retain their ability to bind. As expected, the deletion mutant lacking the first two residues of wild-type GBP ((3–25)-GBP) efficiently antagonized the plasmatocyte-stimulating activity of wild-type GBP, suggesting that (3–25)-GBP still retains critical determinants for receptor binding (Fig. 6). However, the additional deletion of Phe3 ((4–25)-GBP) from the N terminus, or all of the residues in the N-terminal disordered region ((7–25)-GBP) led to dramatic reductions in their ability to antagonize relative to (3–25)-GBP. These data clearly indicated that Phe3 is a critical residue for receptor binding of GBP. Additionally, the (7–25)-GBP did not antagonize the stimulating activity of wild-type GBP at all, implying an inability of the core domain of GBP to bind to the putative receptor without the disordered N-terminal region. The N-terminal hexapeptide ENFSGG alone also exhibited no antagonistic activity (data not shown). These results suggest that when the N terminus and the core domain of GBP are separated that neither has the capacity for a stable peptide-receptor interaction. Based on these findings, it seems reasonable that the linker region between the two domains makes it possible for them to synergistically bind to the putative receptor by anchoring the N-terminal domain to the core domain. Our data clearly demonstrate that Phe3 is the most important source of the binding energy in the N-terminal domain. Furthermore, (4–25)-GBP slightly exhibited antagonistic activity only at a concentration of 100 µM, whereas (7–25)-GBP almost completely lacked the activity, suggesting that the linker region, containing Gly5 and Gly6, is also involved to some extent in receptor binding. We also examined whether the (3–25)-GBP mutant antagonizes the mitogenic activity of wild-type GBP. Interestingly, in contrast to its ability to antagonize plasmatocyte-stimulating activity, the mitogenic activity was not antagonized by (3–25)-GBP (data not shown). These results support our previous proposal that mitogenic and plasmatocyte-stimulating activities may be mediated by different types of GBP receptors (10).



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 6.
In vitro antagonism of plasmatocyte stimulating activity by inactive deletion mutants. The collected hemocytes were treated with 100 nM wild-type GBP after a 10-min preincubation with 1 nM to 100 µM of the deletion mutants (7–25)-GBP, (4–25)-GBP, and (3–25)-GBP. Spreading was assayed 20 min after the addition of wild-type GBP as described in Fig. 4.

 
Conformational Dynamics of GBP and the GBP Mutants G5F and G6F—15N NMR relaxation measurements can be used to characterize the intramolecular conformational dynamics of proteins and peptides (23). To elucidate the dynamics of the N-terminal domain of GBP, a set of 15N relaxation data, including R1 (= 1/T1) and R2 (= 1/T2) rates and {1H}-15N heteronuclear NOEs were measured for wild-type GBP and the Gly replacement mutants G5F and G6F at 500 MHz and 25 °C (Fig. 7). Because calculation of Model-free parameters using the Model-free formalism would be impractical due to the lower molecular mass and rotational correlation time of GBP (~2.8kDa), we did not perform a Model-free analysis of the data and extracted only the general trends for dynamic behavior (24–26). In general, it is believed that 15N transverse relaxation rates (R2) lower than the average R2 value for the molecule indicate internal motion. As expected, low R2 values for the disordered N and C termini of GBP were observed, suggesting an increased mobility due to flexibility in these regions. Additionally, much lower NOE intensities were exhibited by both ends of GBP, showing that they are less ordered than the internal domain of the molecule. These results are collectively indicative of a lack of structural definition in these regions and are in agreement with the solution structure of GBP previously determined by 1H NMR spectroscopy (Fig. 2A). Of particular interest is the fact that the G5F mutant exhibited almost the same R2 value as wild-type GBP despite its greater loss of stimulating activity than the G6F mutant, suggesting that Phe substitution at Gly5 has little effect on the mobility of the N-terminal region of GBP. This also implies that the greatly reduced activity of the G5F mutant may be mainly due to steric hindrance between the aromatic side chain of the Phe and the putative binding site of the linker region on the receptor.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 7.
Sequential plots of 15N relaxation parameters for Phe substitutions in the linker region of GBP. 15N longitudinal relaxation rates (R1), 15N transverse relaxation rates (R2), and 1H-15N heteronuclear NOEs were determined for GBP (filled circles) and the mutant peptides G5F (A–C, open triangles) and G6F (D–F, open squares). Experimental conditions were the same as those in Fig. 3 except that peptide concentrations were in the range of 1.6–2.7 mM.

 
Receptor Binding Model of GBP—Together with our previous published data, the results presented here suggest a mechanism by which GBP binds to its putative receptor. First, the initial binding of GBP is most likely mediated by the well structured core domain of GBP. In support of this, mutant peptides that result in a loss of structure, such as the D16{beta} mutant, which contained the {beta}-aspartyl bond between Asp16 and Gly, and double mutant C7.19A, which deleted the disulfide bridge in the core domain, are completely inactive (11, 12). Binding of the core domain to the receptor is then followed by binding of the unstructured N terminus, an interaction mediated primarily by Phe3, as has been demonstrated in both GBP and PSP (11, 13). Because the hexapeptide ENFSGG is both inactive and unable to antagonize, we assume that the interaction of the core domain of GBP with its receptor induces the interaction between Phe3 and a specific binding pocket on the receptor, presumably a hydrophobic cavity. Consequently, the N-terminal activating residue, Glu1, is presented to its complimentary site on the receptor and is ultimately responsible for activating it.

We show here that the linker region of GBP is also essential for its activity. The inherent flexibility of the linker, which permits a high degree of freedom of the conformation of the N terminus, may be required to allow the ENF motif to assume the proper conformation necessary to contact and activate the GBP receptor. The different activities exhibited by the Gly5 and Gly6 mutants may be due to their putative binding site in the receptor, which is likely to adopt a groove-like structure. The higher antagonistic activity of the (4–25)-GBP mutant relative to (7–25)-GBP is also consistent with this model, because it appears that the residues in the linker region also bind with some affinity to the putative binding cavity. This is presumably the reason why (4–25)-GBP had antagonistic activity higher than (7–25)-GBP. In addition to this requirement for flexibility, we show that the length of the linker region is critical for activity. A single Gly addition to the linker region still allows for some receptor activation, but removing a Gly results in a large loss of activity. The decreased length of the N terminus presumably precludes the N-terminal amine from gaining access to its activation site and suggests a highly precise fit between peptide and receptor.

Although the structure of GBP receptor has not yet been reported, recent studies suggesting that the dissociating constant for 125I-labeled GBP in plasmatocytes was 1.26 nM.2 Interestingly, this Kd values for GBP in plasmatocyte were different from that in insect Sf-9 cells, 0.25 nM (8). In accordance with this result, we have previously reported that GBP has multiple activities, and experiments using the GBP mutants suggest that a different type of GBP receptor may mediate each of these activities (10). In the case of mitogenic activity of GBP toward Sf-9 cells, it is likely that the tyrosine phosphorylation of the receptor triggers a series of intracellular signaling events (8). In the case of plasmatocytes stimulation by GBP, however, the signaling mechanism is still unknown. In the present study, we have proposed a model of GBP receptor binding in plasmatocytes that relies on the extensive data provided by the recombinant GBP mutants. The data reported here confirm the significance of the flexible N-terminal region of GBP and are also expected to provide useful clues as to the mechanism of receptor activation in other activities that GBP exhibits such as mitogenic activity in cultured cells.


   FOOTNOTES
 
* This work was supported by the Program for the Promotion of Basic Research Activities for Innovation Biosciences, Japan, and the Ministry of Education, Culture, Sports, Science and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

** To whom correspondence should be addressed. Tel.: 81-11-706-2770; Fax: 81-11-706-4993; E-mail: kawano{at}sci.hokudai.ac.jp.

1 The abbreviations used are: GBP, growth-blocking peptide; PSP, plasmatocyte spreading peptide; HPLC, high performance liquid chromatography; HSQC, heteronuclear single quantum coherence; NOESY, nuclear Overhauser effect spectroscopy; NOE, nuclear Overhauser effect. Back

2 Y. Oda and Y. Hayakawa, unpublished results. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Hayakawa, Y. (1990) J. Biol. Chem. 265, 10813-10816[Abstract/Free Full Text]
  2. Hayakawa, Y. (1991) J. Biol. Chem. 266, 7982-7984[Abstract/Free Full Text]
  3. Hayakawa, Y., and Yasuhara, Y. (1993) Insect Biochem. Mol. Biol. 23, 225-231[CrossRef]
  4. Hayakawa, Y. (1995) J. Insect Physiol. 41, 1-6
  5. Hayakawa, Y., and Ohnishi, A. (1998) Biochem. Biphys. Res. Commun. 250, 194-199[CrossRef][Medline] [Order article via Infotrieve]
  6. Clark, K. D., Pech, L. L., and Strand, M. R. (1997) J. Biol. Chem. 272, 23440-23447[Abstract/Free Full Text]
  7. Skinner, W. S., Dennis, P. A., Li, J. P., Sumerfelt, R. M., Carney, R. L., and Quistad, G. B. (1991) J. Biol. Chem. 266, 12873-12877[Abstract/Free Full Text]
  8. Ohnishi, A., Oda, Y., and Hayakawa, Y. (2001) J. Biol. Chem. 276, 37974-37979[Abstract/Free Full Text]
  9. Aizawa, T., Fujinitani, N., Hayakawa, Y., Ohnishi, A., Ohkubo, T., Kawano, K., Hikichi, K., and Nitta, K. (1999) J. Biol. Chem. 274, 1887-1890[Abstract/Free Full Text]
  10. Aizawa, T., Hayakawa, Y., Ohnishi, A., Fujinitani, N., Clark, K. D., Strand, M. R., Miura, K., Koganesawa, N., Kumaki, Y., Demura, M., Nitta, K., and Kawano, K. (2001) J. Biol. Chem. 276, 31813-31818[Abstract/Free Full Text]
  11. Tada, M., Aizawa, T., Shinohara, Y., Matsubara, K., Miura, K., Yoshida, M., Shitara, K., Kouno, T., Mizuguchi, M., Nitta, K., Hayakawa, Y., and Kawano, K. (2003) J. Biol. Chem. 278, 10778-10783[Abstract/Free Full Text]
  12. Clark, K. D., Volkman, B. F., Thoetkiattikul, H., King, D., Hayakawa, Y., and Strand, M. R. (2001) J. Biol. Chem. 276, 18491-18496[Abstract/Free Full Text]
  13. Clark, K. D., Volkman, B. F., Thoetkiattikul, H., Hayakawa, Y., and Strand, M. R. (2001) J. Biol. Chem. 276, 37431-37435[Abstract/Free Full Text]
  14. Strand, M. R., Hayakawa, Y., and Clark, K. D. (2000) J. Insect Physiol. 46, 817-824[CrossRef][Medline] [Order article via Infotrieve]
  15. Richardson, J. S. (1981) Adv. Protein Chem. 34, 167-339[Medline] [Order article via Infotrieve]
  16. Piatto, M., Saudek, V., and Skelenar, V. (1992) J. Bimol. NMR 2, 661-665
  17. Palmer, A. G., III, Cavanagh, J., Wright, P. E., and Rance, M. (1991) J. Magn. Reson. 93, 151-170
  18. Kay, L. E., Marion, D., and Bax, A. (1989) J. Magn. Reson. 84, 72-84
  19. Mine, S., Tate, S., Ueda, T., Kainosho, M., and Imoto, T. (1999) J. Mol. Biol. 286, 1547-1565[CrossRef][Medline] [Order article via Infotrieve]
  20. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) J. Biomol. NMR 6, 277-293[Medline] [Order article via Infotrieve]
  21. Garrett, D. S., Powers, R., Gronenborn, A. M., and Clore, G. M. (1991) J. Magn. Reson. 95, 214-220
  22. Hayakawa, Y (1994) J. Biochem. 115, 15-17[Abstract/Free Full Text]
  23. Farrow, N. A., Muhandiram, R., Singer, A. U., Pascal, S. M., Kay, C. M., Gish, G., Shoelson, S. E., Pawson, T., Forman-kay, J. D., and Kay, L. E. (1994) Biochemistry 33, 5984-6003[CrossRef][Medline] [Order article via Infotrieve]
  24. Lipari, G., and Szabo, A. (1982) J. Am. Chem. Soc. 104, 4546-4559[CrossRef]
  25. Lipari, G., and Szabo, A. (1982) J. Am. Chem. Soc. 104, 4559-4570[CrossRef]
  26. Parmer, A. G., Rance, M., and Wright, P. E. (1991) J. Am. Chem. Soc. 133, 4371-4380[CrossRef]
  27. Skinner, W. S., Dennis, P. A., and Quistad, G. B. (1993) Comp. Biochem. Physiol. 104, 133-135[CrossRef]
  28. Seino, A., Sato, Y., Yamashita, T., Sato, Y., and Suzuki, K. (1998) J. Seric. Sci. Japan 67, 473-478
  29. Ha, S.-D., Nagata, S., Suzuki, A., and Kataoka, H. (1999) Peptides 20, 561-568[CrossRef][Medline] [Order article via Infotrieve]
  30. Furuya, K., Hackett, M., Cirelli, M. A., Schegg, K. M., Wang, H., Shabanowitz, J., Hunt, D. F., and Schooley, D. A. (1999) Peptides 20, 53-61[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/49/51331    most recent
M409382200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshida, M.
Right arrow Articles by Kawano, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, M.
Right arrow Articles by Kawano, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.